Since HER2 and EGFR both belong to the ErbB family and share similar downstream pathways [27], further researches could evaluate whether these two mutations play a similar role in immunogenicity, PD-L1 expression, and tumor microenvironment. The gene discussed is EGFR; the disease is neoplasm.